Keith Flaherty MD

Oncology•Boston, MA

Professor, Medicine, Harvard Medical School Director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital

Join to View Full Profile

55 Fruit StLawrence House 202Boston, MA 02114
Phone+1 617-643-5817
Fax+1 617-724-3166

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2000 - 2002
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 2000
Johns Hopkins University School of MedicineClass of 1997

Certifications & Licensure

MA State Medical License 2009 - 2026
FL State Medical License 2015 - 2017
PA State Medical License 2000 - 2010
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
Boston Magazine Castle Connolly, 2010-2013
America's Top Doctors for Cancer Castle Connolly, 2010-2013
Elected Member The American Society for Clinical Investigation, 2012
Join now to see all

Clinical Trials

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers Start of enrollment: 2003 Oct 01
Completed
Phase 1, Phase 2
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2007 Sep 14
Completed
Phase 2
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer Start of enrollment: 2008 Jun 01
Unknown status
Phase 2
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
Completed
Phase 1, Phase 2
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Start of enrollment: 2013 Mar 01
Completed
Phase 1, Phase 2
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma Start of enrollment: 2014 Jul 23
Completed
Phase 2
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab Start of enrollment: 2019 Jun 12
Recruiting
Phase 1
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. Start of enrollment: 2019 May 29
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids.
Yi Sun, Luke Maggs, Apekshya Panda, Samuel J Wright, Angelina M Cicerchia
Cancer Immunology Research. 2025-02-03
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma.
Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana Arance
Future Oncology. 2025-02-01
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.
Mohamed A Gouda, Zihan Wei, Jordi Rodon, Michael A Davies, Filip Janku
JCO Precision Oncology. 2025-02-01

Journal Articles

Effect of Capivasertib in Patients with an AKT1 E17K-Mutated Tumor
Kevin Kalinsky, Edith P Mitchell, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology
Publisher Correction: Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma
Genevieve Boland, Ryan J Sullivan, Keith Flaherty, Nature
A PAX3/BRN2 Rheostat Controls the Dynamics of BRAF Mediated MITF Regulation in MITFhigh/AXLlow Melanoma
Keith T Flaherty, Jennifer A Wargo, Wiley
Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma
Ryan J Sullivan, Genevieve Boland, Keith Flaherty, Nature
When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age
Keith Flaherty, MD, Annals of Internal Medicine
Join now to see all

Lectures

Tissue Agnostic Drug Development Operational and Scientific Challenges. Tissue Agnostic Drug Development
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Press Mentions

Keith T. Flaherty, MD of Mass General Brigham Appointed to Lead AACRMarch 27th, 2025
Lifesaving Protein Kills Cancer Cells and Boosts the Body’s ImmunitySeptember 18th, 2024
Scientists Discover Protein That Eradicates Cancer and Boosts the Body’s ImmunityAugust 15th, 2024
Join now to see all